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A
CD1. Perioperative mortality and morbidity were signifi-
cantly less with an endovascular approach.
2. Spinal cord ischemia was significantly less in the
endograft cohort.
3. The overall stroke rate was similar in both the en-
dograft and open surgical control cohorts.
4. The reintervention rate and continued presence of
complications, such as endoleaks, is higher in the
endograft group. The presence of endoleaks can lead
to future complications, but their significance is still
unclear.
5. There was no survival advantage associated with
either strategy after 2 years of follow-up.
As technology continues to improve and we as surgeons
rogress along the learning curve, the long-term complica-
ions of endografting might or might not be mitigated.
herefore continued vigilant surveillance of patients treated
ith endovascular repair is important.
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iscussion
r Joseph S. Coselli (Houston, Tex). Scott, congratulations on an
utstanding presentation and for bringing this information from a
ulticenter clinical trial to us. I believe that your report will be a
eminal investigation into an evolving technology that stands to
orever alter the way we therapeutically approach descending
horacic aortic pathology. Although I believe that aortic stenting is
ere to stay, we must shun the pressure of industry-driven initia-
ives and pursue good science and good medicine with, of course,
ndustry support. We need to shoulder the responsibility of being
he patient’s primary advocate.
You and the coauthors importantly infer the problems associ-
ted with a nonrandomized multicenter trial. I continue to have
roblems with the control group. Most of the control subjects,
3%, were historically and retrospectively acquired. Not all insti-
utions contributed patients to this cohort. Data on aortic charac-
eristics were unavailable in many of the open reconstruction
ontrol patients. Proximal and distal aortic diameters and aneu-
ysm length, for example, were reported in less than 35% of this
ohort; even aneurysm diameter data were missing in 10%. The
ata support that the open repair group did not end up with more
dvanced disease because they had larger aortic diameters and
ere more likely to be symptomatic.
After endograft repair, 17% of the patients had expansion of
heir aneurysm of greater than 1/2 cm over 2 years. Considering
he need for life-long monitoring after endograft repair, especially
n the setting of a research protocol, incomplete 2-year follow-up
f 14% is concerning. Do you think that 2 years really is enough?
and Cardiovascular Surgery ● Volume 133, Number 2 375
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A
CDThe extent of aorta replaced and the location (ie, proximal or
istal or the entire descending thoracic aorta) are related to mor-
idity, primarily stroke and paraplegia. Were comparisons made
etween these 2 groups accounts for these?
Seventy-eight percent of the open repairs had extracorporeal
upport. Was this need for cardiopulmonary bypass and hypother-
ic circulatory arrest suggestive of extensive disease and associ-
ted with increased morbidity or mortality?
One patient died of an aortoesophageal fistula. What do you
elieve the nature of that particular fistula was, how did it occur,
nd what lessons do you think were learned?
The incidence of paraplegia and paraparesis after endovascular
epair was 5% in patients with prior AAA repair. What was the
ncidence of paraplegia or paraparesis after previous AAA repair
n the open group?
The incidence of stroke in the treatment group was 4%. With
he need to traverse the aortic arch with a stiff wire and, for
roximal aneurysms, even advance the deployment device into the
rch, do you and the authors see a need for transesophageal
chocardiography to evaluate the arch for mobile atherosclerotic
isease before implementation of the device?
Using a 30% increase in baseline creatinine level to define
renal dysfunction” as a cutoff point captures patients with clini-
ally insignificant increases. Therefore what was the incidence of
ostoperative dialysis in the 2 groups?
The study excluded patients with recent myocardial infarction
r recent stroke, renal insufficiency, and respiratory insufficiency,
nd interestingly enough, these are the patients in particular who
ight benefit the most from endovascular repair.
Once again, congratulations.
Dr Mitchell. Thank you, Dr Coselli. I will try and answer as
any of your questions as I can remember.
First, is 2 years enough? Absolutely not. We do not know the
xact hazard function, but I think these complications will be
ngoing, hopefully decreasing with time, but we do not know that.
herefore these patients will require lifelong follow-up.
The question of the control group has been an energized dis-
ussion. It is not the best control group, we admit that, but it is the
nly one that we had, and I think all of us are aware of the
ifficulties in trying to get a very aware public to enroll in a
andomized trial.
I cannot answer about the incidence of paraplegia in the open
nd control group as relates to previous abdominal aneurysm
epairs. p
76 The Journal of Thoracic and Cardiovascular Surgery ● FebrAs relates to cardiopulmonary bypass, that was used primarily
s an adjunct for each individual site in their routine repair of
escending thoracic aneurysms, and, in theory, circulatory arrest
nd hypothermia were not supposed to be used for these patient
opulations because they were supposed to be clampable.
Finally, we do agree that transesophageal echocardiography
s an invaluable adjunct for the anesthetic management of these
atients to look at the arch. There is no question that any
anipulation in the arch does predispose this patient population
o stroke, even as little as a stiff guide wire, and certainly,
aving to put your sheath through the arch increases that risk
ven more.
Dr Coselli. Scott, one quick follow-up. You and your group at
tanford have the longest and probably the largest experience with
his particular technology. Would you just comment on your
houghts regarding connective tissue disease, particularly Marfan’s
yndrome, applying this approach?
Dr Mitchell. I think you noticed that patients with Marfan’s
yndrome were specifically excluded from this, and I would con-
inue to urge that to be an exclusion with the exception of replacing
ome remnant aorta between 2 Dacron segments. Therefore if you
re connecting Dacron to Dacron, I think that would be okay.
therwise, I would be very pessimistic that this would be effec-
ive.
Dr Michael C. Maxwell (Mesa, Ariz). The Achilles’ heel of
ndoluminal grafting is the endoleak, and I noticed you had a 15%
ncidence. I talked to other investigators for this graft in the thoracic
osition, and endoleak, particularly type I, seems to be more common
han it is in the abdominal position. Is that something you have also
oticed, and if so, is it something that can be watched, unlike in the
bdominal position, or does it have to be taken care of when identi-
ed?
Dr Mitchell. No, I think type I endoleaks should be managed
n detection. Type II and III endoleaks perhaps can be followed,
ooking at aneurysmal sac size as a surrogate. But we have been
ery aggressive about trying to eliminate all type I endoleaks.
There was just one question I forgot to answer for Dr Coselli,
hat there were some aneurysm enlargements that were unassoci-
ted with endoleaks. This is the so-called endotension, which did
ccur with the old graft because it was thinner. The new revised
raft has a stouter polytetrafluoroethylene column, and we do not
hink that these transmembrane leaks will occur, and hopefully this
henomenon will go away.
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